| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary antifungal target is lanosterol 14α-demethylase (CYP51), inhibition of which depletes ergosterol and disrupts fungal membrane integrity; ketoconazole also inhibits CYP17 (17α-hydroxylase/C17,20-lyase), CYP11B1, and CYP3A4, with IC50 values for steroidogenic cytochromes in the range of 0.5–1.0 μg/mL, thereby suppressing androgen and cortisol synthesis at higher concentrations.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, (-)-ketoconazole-d3 inhibits fungal CYP51 and mammalian CYP17 with enantiomer-dependent potency; it suppresses testosterone biosynthesis in testicular microsomes by inhibiting 17α-hydroxylase and C17,20-lyase activities in a dose-dependent manner, and it inhibits ovarian steroidogenesis with IC50 values of approximately 0.5–1.0 μg/mL for P450scc, P45017α, and P450arom. |
| ln Vivo |
In vivo, ketoconazole reduces serum androgen levels in patients with polycystic ovary syndrome and in men with prostate cancer, and it lowers cortisol production in Cushing syndrome at doses of 400–1200 mg/day; the (-)-enantiomer contributes to CYP17 inhibition, and the deuterated form is used to quantify enantiomer-specific exposure and metabolic clearance in animals and humans.
|
| Enzyme Assay |
Noncellular assays incubate recombinant human CYP17 or testicular microsomes with progesterone or pregnenolone and increasing concentrations of (-)-ketoconazole-d3 in the presence of NADPH; steroid metabolites are quantified by high-performance liquid chromatography or mass spectrometry, and IC50 values are derived for 17α-hydroxylase and C17,20-lyase activities, with CYP51 inhibition assessed using lanosterol as substrate.
|
| Cell Assay |
Cellular assays use adrenal H295R or ovarian granulosa cells treated with (-)-ketoconazole-d3 and stimulated with forskolin or angiotensin II; steroid hormones (cortisol, androstenedione, testosterone, estradiol) are measured in conditioned medium by immunoassay or mass spectrometry, and CYP17 and CYP11B1 mRNA expression is quantified by quantitative polymerase chain reaction.
|
| Animal Protocol |
Animal protocols administer (-)-ketoconazole-d3 orally to rats or dogs at doses of 10–100 mg/kg, followed by serial blood sampling for enantioselective pharmacokinetics and measurement of serum testosterone, cortisol, and adrenal steroids; tissue distribution and CYP17 occupancy are assessed ex vivo, and the deuterated tracer allows discrimination from endogenous steroids and metabolites.
|
| References |
| Molecular Formula |
C26H28CL2N4O4
|
|---|---|
| Molecular Weight |
531.430924415588
|
| Exact Mass |
533.167
|
| CAS # |
1217766-70-5
|
| Related CAS # |
(-)-Ketoconazole;142128-57-2
|
| PubChem CID |
76973198
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
753.4±60.0 °C at 760 mmHg
|
| Flash Point |
409.4±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
3.55
|
| tPSA |
69.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
36
|
| Complexity |
735
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(N1C=NC=C1)[C@@]1(C2C=CC(Cl)=CC=2Cl)OC[C@@H](COC2C=CC(N3CCN(C(=O)C([H])([H])[H])CC3)=CC=2)O1
|
| InChi Key |
XMAYWYJOQHXEEK-SIULDFEJSA-N
|
| InChi Code |
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1/i1D3
|
| Chemical Name |
2,2,2-trideuterio-1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8817 mL | 9.4086 mL | 18.8172 mL | |
| 5 mM | 0.3763 mL | 1.8817 mL | 3.7634 mL | |
| 10 mM | 0.1882 mL | 0.9409 mL | 1.8817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.